Analytical Data
-
Gene name
HLA-A*01:01&B2M&CT83(NTDNNLAVY) Tetramer
- Application
-
Alternative Names
Cancer/testis antigen 83; KK-LC-1
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q5SUL5 (G25-T305)&P61769
-
Expression Region
Q5SUL5 (G25-T305)&P61769 (I21-M119)&NTDNNLAVY
-
Molecular Weight
260-265 kDa under Non reducing (N)
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The HLA-A*01:01&B2M&CT83(NTDNNLAVY) tetramer is a recombinant protein that plays a crucial role in the study of cancer immunology and T cell responses. HLA-A*01:01 is a well-characterized human leukocyte antigen (HLA) class I molecule, essential for presenting peptides to CD8+ T cells, thus facilitating immune recognition of tumor cells. The CT83 peptide (NTDNNLAVY) is derived from the CT83 antigen, which is expressed in various malignancies, making it a promising target for cancer immunotherapy. The creation of tetramers, which consist of four copies of the peptide-HLA complex, enables the precise identification and isolation of CT83-specific T cells from peripheral blood or tumor samples. This has important implications for understanding tumor immune evasion mechanisms, monitoring the effectiveness of immunotherapies, and developing personalized T cell therapies. By utilizing HLA-A*01:01 tetramers, researchers can delve deeper into T cell repertoire analysis, promoting the advancement of therapeutic strategies aimed at enhancing anti-tumor immunity and improving patient outcomes in cancer treatment.
